A new study suggests that levetiracetam, a common seizure medication, may prevent the onset of Alzheimer's disease but must be taken decades before symptoms arise.
A recent study conducted by Northwestern Medicine has identified levetiracetam, a widely used anti-seizure drug, as a potential medication that could prevent Alzheimer's disease. Researchers found that this common medication may inhibit the build-up of toxic proteins in the brain that lead to the development of Alzheimer's symptoms. The study underscores the importance of early intervention, as it suggests that levetiracetam would need to be taken nearly 20 years prior to any detectable signs of the disease, presenting a challenge in practical application for at-risk individuals.
The research highlights how the accumulation of these toxic proteins, which are known contributors to Alzheimer’s, can be halted by utilizing existing medications in novel ways. This presents a significant shift in the understanding of treatment options for Alzheimer’s disease, as traditional medications focus on alleviating symptoms rather than preventing disease onset. The findings not only suggest a promising new direction for drug application but also pave the way for further research aimed at understanding the timeline and mechanisms of protein accumulation in the brain.
However, the implications of these findings raise important questions regarding accessibility and the practicality of administering such preventive treatments over long periods. Given that Alzheimer’s symptoms may only appear decades after protein changes begin in the brain, it necessitates a discussion regarding screening for those who are currently asymptomatic yet may be at higher risk. The discovery calls for collaboration across the medical community to explore comprehensive strategies for preemptive care in Alzheimer’s disease.
